Zealand’s Dasiglucagon Down But Not Out In CHI?
Executive Summary
Zealand has been hit by an unexpected Phase III failure for its glucagon analog product dasiglucagon in congenital hyperinsulinism, but all may not be lost for the indication.
You may also be interested in...
Zealand Pharma Preps Pipeline For Catalyst-Filled 2020
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.
Another Failure For Biohaven’s Troriluzole
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports